Which got me to thinking. A comparable industry, cryopreservation, is able to support a viable company (Alcor). I believe the reason is that Alcor has a sustainable business model- folks pay for a policy, and in return their contract promises they'll be cryopreserved once they kick the bucket.
SENS is Aubrey's age prevention outfit. SENS relies mostly donations for funding. Their budget pales in comparison to comparable ventures to fight cancer, Alzheimer's etc. I'm persuaded by Aubrey's argument that this reality is not ideal- for a number of reasons, research into expanding the healthspan offers a better benefit/cost ratio than research into treating low frequency diseases.
I think a primary problem here is the lack of an investment-attracting business model. I also think there are several possible business models that could help solve this problem and accelerate research into healthspan-expanding medical advances. Which do you find most tenable? What others can you think of?